オテラシル
WordNet
- a light soft silver-white metallic element of the alkali metal group; oxidizes rapidly in air and reacts violently with water; is abundant in nature in combined forms occurring in sea water and in carnallite and kainite and sylvite (同)K, atomic number 19
PrepTutorEJDIC
- ポタシウム,カリウム(金属元素;化学記号はK)
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
- Otsuka H1, Fujii T, Toh U, Iwakuma N, Takahashi R, Mishima M, Takenaka M, Kakuma T, Tanaka M, Shirouzu K.
- Breast cancer (Tokyo, Japan).Breast Cancer.2015 Jul;22(4):335-42. doi: 10.1007/s12282-013-0483-1. Epub 2013 Jul 5.
- BACKGROUND: We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransfera
- PMID 23827973
- A Successful Case of a Patient Undergoing Warfarin and S-1 Therapy Using Internet-based Control of Home-measured PT-INR.
- Yamamura K1, Yano K, Hirooka Y, Hirashiki A, Murohara T, Yamada K.
- Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.Yakugaku Zasshi.2015 Jul 1;135(7):925-7. doi: 10.1248/yakushi.15-00016. Epub 2015 Apr 24.
- To avoid major bleeding events in warfarin and S-1 combination therapy, PT-INR levels should be monitored frequently to allow for precise adjustments of the warfarin dose and to verify any side effects reported by the patient. We therefore developed a support system where outpatients obtain a ho
- PMID 25913669
- Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting.
- Kimura M1, Nakashima K1, Usami E1, Iwai M1, Nakao T1, Yoshimura T1, Mori H1, Teramachi H2.
- Oncology letters.Oncol Lett.2015 May;9(5):2341-2346. Epub 2015 Mar 11.
- The aim of the present study was to clarify the adherence and awareness of oral anticancer agents by type and therapeutic purpose in outpatients prescribed with tegafur/gimeracil/oteracil potassium (S-1) or capecitabine. Outpatients undergoing treatment with the S-1 or capecitabine oral anticancer a
- PMID 26137068
Japanese Journal
- ジェネリック医薬品の生物学的同等性試験データ情報集 テガフール・ギメラシル・オテラシルカリウム配合剤
- 木村 章嗣,吉良 慎一郎,小出 晴久 [他],鈴木 鑑,森武 潤,平本 有希子,冨田 雅之,清田 浩,頴川 晋,石山 守,吉田 和彦,酒田 昭彦
- 泌尿器科紀要 = Acta urologica Japonica 61(3), 95-98, 2015-03
- … The patient has been receiving adjuvant chemotherapy with tegafur-gimeracil-oteracil potassium for 17 months, because he refused right hemicolectomy. …
- NAID 120005611369
- A Successful Case of a Patient Undergoing Warfarin and S-1 Therapy Using Internet-based Control of Home-measured PT-INR
- 山村 恵子,矢野 亨治,廣岡 芳樹,平敷 安希博,室原 豊明,山田 清文
- 薬学雑誌. 乙号 135(7), 925-927, 2015
- … A 59-year-old man was started on warfarin (1.5 mg/d) and S-1 (100 mg/d), a combination preparation of tegafur, gimeracil, and oteracil potassium, to treat cholangiocarcinoma. …
- NAID 130005085765
★リンクテーブル★
[★]
- 英
- oteracil
- 化
- オテラシルカリウム oteracil potassium
- 商
- ティーエスワン配合